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ABSTRACT
Objectives: Hospital-acquired bloodstream infections
are known to increase the risk of death and prolong
hospital stay, but precise estimates of these two
important outcomes from well-designed studies are
rare, particularly for non-intensive care unit (ICU)
patients. We aimed to calculate accurate estimates,
which are vital for estimating the economic costs of
hospital-acquired bloodstream infections.
Design: Case–control study.
Setting: 9 Australian public hospitals.
Participants: All the patients were admitted between
2005 and 2010.
Primary and secondary outcome measures: Risk
of death and extra length of hospital stay associated
with nosocomial infection.
Results: The greatest increase in the risk of death was
for a bloodstream infection with methicillin-resistant
Staphylococcus aureus (HR=4.6, 95% CI 2.7 to 7.6).
This infection also had the longest extra length of stay
to discharge in a standard bed (12.8 days, 95% CI 6.2
to 26.1 days). All the eight bloodstream infections
increased the length of stay in the ICU, with longer
stays for the patients who eventually died (mean
increase 0.7–6.0 days) compared with those who were
discharged (mean increase: 0.4–3.1 days). The three
most common organisms associated with Gram-
negative infection were Escherichia coli, Pseudomonas
aeruginosa and Klebsiella pneumonia.
Conclusions: Bloodstream infections are associated
with an increased risk of death and longer hospital
stay. Avoiding infections could save lives and free up
valuable bed days.
INTRODUCTION
Hospital-acquired infections increase a
patient’s risk of death and prolong their hos-
pital stay.1 Accurate estimates of the
increased risk of death and extra length of
stay are rare because of the complex statis-
tical analysis needed to avoid the potentially
serious biases of ignoring the timing of infec-
tion.2 3 There are few accurate estimates of
the extra length of stay and increased risk of
death due to bloodstream infections (BSI),4
with most good estimates only for patients in
intensive care unit (ICU). This is an import-
ant gap in our understanding of the com-
plete burden of hospital-acquired BSIs,
particularly as death and length of stay are
vital for estimating the economic costs of
hospital-acquired infections.5–7 Also, ﬁnan-
cial penalties are applied in some hospitals
for any hospital-acquired BSI (not just
central line associated BSI).
In this paper, we used an analysis that
accounts for the timing of infection and
hence gives accurate estimates of the risk of
death and extra length of stay. We examined
eight types of hospital-acquired BSIs using
data from nine Australian hospitals over
6 years. We estimated the extra length of
stay due to infections for standard and ICU
beds.
METHODS
Data
We examined the nine largest public hospi-
tals in Queensland, Australia (see table 1 for
some descriptive statistics). We requested all
Strengths and limitations of this study
▪ We had an extremely large sample size but with
little detailed individual information. We could
not therefore match or control for detailed indi-
vidual characteristics, which may mean that there
is some residual confounding in our estimates.
▪ Our estimates will be useful for economic
studies on the costs and health benefits of inter-
ventions that reduce hospital-acquired infections.
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patient admissions with an admission or discharge date
between 1 January 2005 and 31 December 2010 from
the Health Statistics Centre of Queensland Health. The
infection data came from the Centre for Healthcare
Related Infection Surveillance and Prevention
(CHRISP), Queensland Health. The admission and
infection data were linked by the Queensland Health
staff using a unique patient unit record number and
infection date.
The data used included the dates of admission, dis-
charge and infection (if any), and the dates (if any) of
admissions and discharges from ICU. Data were also
requested on the admitting hospital, patient’s age, prin-
cipal diagnosis code (international classiﬁcation of dis-
eases (ICD)-10) and outcome in three categories:
discharged alive, died or censored. Censored meant the
outcome of the patient was unknown, which occurred
when: (1) the patient was transferred to another hos-
pital, (2) the patient was discharged to some other facil-
ity, such as an aged care facility or medi-hotel. We
accounted for this censoring in our analyses using statis-
tical censoring.
CHRISP coordinates a state wide healthcare associated
infection surveillance programme, which aggregates and
assures the data quality. The surveillance deﬁnitions and
processes have been reﬁned and validated over
10 years,8 and are consistent with national and inter-
national deﬁnitions. Hospitals monitor infections
hospital-wide as detailed in the surveillance manual.9
The data undergo a central quality assurance check
every 6 months, and the observed numbers of infections
are regularly compared with the expected numbers.
Hospitals with numbers that are lower than the state-
wide control limit are asked about their surveillance
processes.
Bloodstream infections were classiﬁed a priori into four
non-mutually exclusive groups, those due to:
(1) Staphylococcus aureus, (2) coagulase negative staphylo-
cocci, (3) Gram-positive organisms and (4) Gram-negative
organisms. After examining the results from these four
groups, we added four further subgroups. For example, S
aureus infections were split into methicillin-resistant S aureus
(MRSA) and methicillin-sensitive S aureus (MSSA), and
Gram-negative organisms were split into Escherichia coli and
Pseudomonas aeruginosa, to examine a lower and higher viru-
lence organism, respectively. The infection groups are not
mutually exclusive. For example, BSIs due to S aureus were
also classiﬁed in the Gram-positive organism group.
Community associated infections were excluded. The
portal of entry of BSI (eg, urinary tract infection, pneu-
monia, intra-abdominal infection, central line) was not
available.
Statistical methods
The basis of our statistical model is shown in ﬁgure 1.
A patient’s admission over time is modelled using the
four states, with all patients eventually dying or being
discharged, and some patients being infected. Using this
multistate model, we can examine our two key questions
1. By how much did a hospital-acquired BSI increase
the risk of death?
2. By how much did a hospital-acquired BSI increase
the length of stay?
Incidence density sampling
We created a smaller group of infected and non-infected
patients from the complete data using incidence density
sampling.10 The incidence density sampling approach is
illustrated in ﬁgure 2. Patient E is the infected case,
whose infection occurred 4 days after their admission.
Patient D is not a potential control, as he was discharged
alive before day four. The other three patients (A–C)
Figure 1 Four-state model to estimate the extra risk of death
and extra length of stay due to a hospital-acquired
bloodstream infection. The arrows represent hazards in a
survival model. The extra risk of death was estimated using
the HR of the hazard of death for infected patients (arrow A)
and the hazard for susceptible patients (arrow C). The extra
length of stay for those discharged alive was calculated by
comparing the time taken to discharge for infected patients
(arrow B) with the time taken to discharge for susceptible
patients (arrow D).
Table 1 Basic characteristics of the nine Queensland hospitals combined, patients with admission or discharge dates
between 1 January 2005 and 31 December 2010
Admissions Numbers Patient age, median (IQR) LoS in days, median (IQR) In-hospital deaths (%)
All 2 725 515 53 (32, 69) 1 (1, 4) 1.1
Those with an infection 19 206 61 (44, 74) 15 (6, 31) 7.1
Those without an infection 2 706 309 53 (32, 69) 1 (1, 4) 1.0
Results for all admissions and admissions by infection status.
LoS, length of stay.
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are all eligible controls as they were infection free at the
time of the case’s infection. This includes patient C, who
acquired an infection on a later day.
The days in hospital after the infection (for both cases
and controls) were used to estimate the extra length of
stay (solid lines in ﬁgure 2). We examined the extra
number of days in standard and ICU beds (thin and
thick lines in ﬁgure 2, respectively). For patients with
multiple infections, we only considered their ﬁrst infec-
tion. This was performed to simplify the analysis (as mul-
tiple infections would require another state in ﬁgure 1),
and because there were relatively few admissions with
multiple infections.
Matching infected patients to control patients when
estimating the extra length of stay due to infection
usually gives poor estimates because of the time-
dependent bias.5 This bias occurs because the time
before infection is used when estimating the extra
length of stay (dashed horizontal lines in ﬁgure 2).
However, unlike traditional matching studies, we used
incidence density sampling, which also matches the
timing of infection because potential controls must have
been infection-free at the time of the case’s infection.10
To make comparable groups of patients in terms of
morbidity, we matched infected cases to controls who:
had the same ﬁrst letter in the principal diagnosis code
(using ICD-10 coding), were of a similar age (within
10 years), were at the same hospital, and were infection-
free at the time of the case’s infection. We randomly
selected four controls for each of the infected patients.
Statistical power
The study had a 90% power to detect an increased HR
of 1.40 (40%) for infected versus uninfected patients
using the smallest number of infections of 189 for
MRSA, and an increased HRs of 1.18 (18%) for the
second smallest number of infections of 744. These cal-
culations assumed a two-sided 5% signiﬁcance level.
We only examined the risk of in-hospital death, as we
had no information on patients after discharge.
Extra length of stay
We estimated the extra length of stay due to infection
using the following steps. We calculated the number of
days from infection to discharge for cases, and the
number of days from the case’s infection to discharge
for its four matched controls. We then subtracted the
case’s length of stay from the average length of stay for
its matched controls, with separate estimates for stays in
standard and ICU beds. We then averaged these individ-
ual extra lengths of stay over all cases. These averages
were stratiﬁed to create separate estimates for patients
discharged alive and dead.
There are no parametric equations for calculating CIs
for the extra length of stay; hence, we used a bootstrap
method to generate a 95% CI.11 We randomly selected
sets of cases and matched controls with replacement,
creating a random sample with the same sample size as
the original data. We repeated this random selection
1000 times.
All analyses were conducted in R V.2.15.0 using the
‘survival’ library.
RESULTS
Hazard ratios
The HRs for the eight BSIs are in table 2. All the eight
infections increased the risk of death, with the largest
risk for MRSA (HR=4.6) and the smallest for
Gram-negative BSI (HR=2.1). The increases were statis-
tically signiﬁcant for all the eight infections, as the lower
limits of the 95% CIs were all above 1. The greatest
number of infections was 2141 for Gram-positive BSI,
and the smallest number was 189 for MRSA.
Extra length of stay
The extra lengths of stay for the eight BSIs are in table 3.
For the patients who died, there was no extra length of stay
in a standard bed (as all the 95% CIs include 0). For the
patients who were discharged alive, infection was asso-
ciated with an extra length of stay in a standard bed for
every type of BSI except the Gram-negative BSIs. The
longest extra length of stay to discharge in a standard bed
was 12.8 days for MRSA (95% CI 6.2 to 26.1 days). The
95% CIs are noticeably wider for infections with smaller
numbers.
Most of the BSI types were associated with an extra
length of stay in the ICU for the patients who lived as
well as those who died (table 3). The extra lengths of
stay were generally longer for those patients who died.
The longest extra length of stay to death in an ICU bed
was 6.0 days for a BSI with coagulase-negative staphylo-
cocci (CNS) (95% CI 3.3 to 10.0 days).
Figure 2 Illustration of incidence density sampling for an
infected case (patient E) and matched controls (patients A to
C). The vertical dotted line shows the timing of infection. The
dashed lines show the periods of hospital stay before
infection. These times are discarded, as only times after
infection are used to estimate the extra length of stay. The
thicker solid lines show the time spent in the ICU. Adapted
from Wolkewitz et al.10
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CONCLUSION
This is one of the largest studies to estimate the
increased length of stay and risk of death due to
hospital-acquired infection.4 All the eight BSI types
studied increased the risk of death and most led to extra
days in the ICU. Five of the BSIs also prolonged stay in a
standard hospital bed by an average of between 9.8 and
12.8 days. The eight hospital-acquired infections studied
therefore signiﬁcantly increased mortality and morbidity.
Gram-negative infections had generally shorter extra
lengths of stay and lower risks of death compared with
the other infection types. The three most common
organisms associated with Gram-negative infection were
E coli, Pseudomonas aeruginosa and Klebsiella pneumoniae.
There were no clear differences between patients with a
Gram-positive and Gram-negative infection in terms of
their age or primary diagnosis (data not shown). BSI
with CNS had a higher death risk (HR=2.9) than
Gram-negative BSIs (HR=2.1), which could reﬂect the
higher risk of an organ failure.12
The average extra lengths of stay after infection were
shorter for ICU bed days compared with ward bed days
for all infections, which is expected as the average extra
length of stay is proportional to the average total length
of stay.2
MRSA was associated with the largest increased risk of
death (HR=4.6) and the largest increase in length of
stay for a standard bed (12.8 days for those discharged
alive). BSI with CNS had the largest increased length of
stay in an ICU bed of 6 days for patients who died and
1.4 days for patients who were discharged alive. These
estimates of HR and length of stay are similar to those
from related studies that account for the time-
dependent bias. A study in European hospitals found
HRs of 3.5 due to MRSA BSI and 3.1 for MSSA BSI, with
an extra length of stay of 9.2 days for MRSA BSI and
8.6 days for MSSA BSI.13 Results from ICUs in 10
European countries gave estimated HRs for BSIs ranging
from 2.1 to 4.4 depending on the organism, and extra
lengths of stay in the ICU ranging from 0.1 to 3.7 days.1
ICUs in France had an estimated OR for death of 3.2
due to a BSI infection, with a lower OR of 2.7 for those
who received appropriate treatment.14
Study limitations
We used a large routinely collected data set of all hos-
pital admissions. Larger data sets give more statistical
power, but are often not as detailed or error-free as pro-
spectively collected data. The hospital admission data
used here are subject to data checking at the time of
entry, and we subjected the data to further logical
checks and found no errors.
We matched controls to cases using the ﬁrst letter of
the ICD-10 code so that the controls and cases were
broadly similar in terms of morbidity. It is possible that
even after the matching, the infected cases were sicker
than the controls (prior to the infection) and that this
somewhat explains the cases’ extra length of stay and
increased risk of death. However, adjusting for the
timing of infection (which we did) is far more important
than adjusting for baseline morbidity when estimating
the extra length of stay due to infection.15
Despite using hospital-wide surveillance, some infec-
tions may have been missed. Surveillance relies on clin-
ical testing, so an infected but untested patient would be
missed. However, collection of blood cultures is standard
for patients with a fever during hospitalisation.
Our results should be generalisable to other settings,
but it is possible that differences will occur depending
on how infections are managed. For example, some hos-
pitals use hospital in the home schemes, where infected
patients can be cared for at home rather than in the
hospital.16 Caring for infected patients in their own
home would reduce the extra length of hospital stay due
to infection. Unfortunately, we did not have data on the
use of hospital in the home and therefore could not esti-
mate the entire patient journey. If we had these data,
Table 2 Risks of in-hospital death due to a hospital-acquired bloodstream infection
Bloodstream
infection
Number of
infections
Deaths in infections,
n (%) Controls
Deaths in controls,
n (%) HR (95% CI)
BSI and Gram
positive
2141 338 (15.8) 8512 526 (6.2) 3.0 (2.6 to 3.5)
BSI with SAB
All 744 124 (16.7) 2950 175 (5.9) 3.5 (2.7 to 4.6)
MRSA 189 38 (20.1) 740 45 (6.1) 4.6 (2.7 to 7.6)
MSSA 555 86 (15.5) 2218 121 (5.5) 3.4 (2.5 to 4.7)
BSI with CNS 918 139 (15.1) 3640 219 (6.0) 2.9 (2.3 to 3.7)
BSI and Gram negative
All 2044 285 (13.9) 8089 609 (7.5) 2.1 (1.8 to 2.4)
Escherichia coli 465 57 (12.3) 1838 130 (7.1) 2.0 (1.4 to 2.8)
Pseudomonas 449 74 (16.5) 1771 163 (9.2) 2.2 (1.6 to 3.0)
Based on nine hospitals with admissions between 1 January 2005 and 31 December 2010.
BSI, bloodstream infection; CNS, coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; SAB, S aureus
bacteraemia.
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they could have been added as another state to the mul-
tistate model in ﬁgure 1.
We had no data on why the extra length of stay
occurred. For example, the extra lengths of stay may be
directly due to the increased morbidity of infection, or
they could be due to a change in patient management,
such as the use of deﬁned durations of intravenous anti-
biotics (such as for S aureus BSI). It is also possible that
the total extra length of stay after a BSI is not solely due
to the infection. For example, a patient’s stay is initially
extended because of a BSI; then during this extra stay,
an unrelated adverse event happens, for example, an
adverse drug reaction that keeps them in hospital for
longer.17 To further investigate extra length of stay due
to infection, we recommend a detailed individual study
that follows patients from the time of their infection to
discharge and details the decisions made and resources
used.18 In some hospitals, this is already collected using
a postinfection review.
Study strengths
This is one of the ﬁrst studies to accurately estimate the
extra length of stay due to BSI in a standard hospital
bed, as most previous good estimates only examined
ICU beds. This is important because days in the hospital
are costly, so extra length of stay is key to determining
the economic costs of infection,19 as well as being an
important measure of morbidity. ICU beds have a far
greater economic cost than standard beds, so it is vital to
get separate estimates for ward and ICU beds.20
Our results can be used to inform parameters for
studies of the cost-effectiveness of interventions that
reduce risks of hospital-acquired infection. This is the
most useful application of estimates, as only describing
the size of the cost does not help decision-makers,
although it might get the attention of politicians and
the media in the short term. Also, erroneous estimates
of these parameters might have misled decision-making
in the past.5 The application of a multistate modelling
approach (ﬁgure 1), which appropriately classiﬁes
patient risks over time, should become the gold standard
method for these studies.3
A key parameter in cost-effectiveness models is the
extra number of deaths, as the years of life lost have a
potentially large economic cost. We found that all the
eight types of BSIs increased the risk of death. Avoiding
infections is therefore likely to save lives and free up
valuable bed days.
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Table 3 Extra length of stay (in days) in a standard bed and ICU bed due to a hospital-acquired bloodstream infection
Bloodstream Standard bed ICU bed
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BSI with SAB
All −1.5 (−6.8 to 6.1) 12.1 (6.7 to 15.3) 1.4 (0.5 to 3.0) 0.9 (0.1 to 2.9)
MRSA −1.6 (−12.6 to 12.6) 12.8 (6.2 to 26.1) 3.1 (0.5 to 7.2) 3.1 (0.4 to 13.2)
MSSA 2.7 (−2.6 to 9.7) 11.0 (6.4 to 14.9) 0.7 (−0.3 to 2.0) 0.4 (0.0 to 0.8)
BSI with CNS 3.5 (−4.0 to 13.4) 9.8 (3.6 to 14.6) 6.0 (3.3 to 10.0) 1.4 (0.6 to 2.5)
BSI and Gram negative
All −3.9 (−8.7 to −0.4) 2.7 (−4.1 to 6.1) 3.0 (1.4 to 4.5) 0.6 (0.3 to 1.0)
Escherichia coli −3.3 (−9.3 to 7.9) 1.1 (−13.2 to 5.7) 2.5 (0.4 to 4.7) 0.5 (−0.1 to 0.9)
Pseudomonas −5.4 (−11.6 to 9.2) 5.6 (−6.4 to 14.3) 3.2 (0.8 to 7.1) 0.5 (0.3 to 1.2)
Cells show the mean extra length of stay (in days) with 95% CIs in parentheses. Based on nine hospitals with admissions between 1 January
2005 and 31 December 2010. Separate estimates were made for admissions that ended in death and discharge. The total length of stay is
the standard bed time plus the ICU bed time (see figure 2).
BSI, bloodstream infection; CNS, coagulase-negative staphylococci; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus
aureus; MSSA, methicillin-sensitive S aureus; SAB, S aureus bacteraemia.
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